Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 3:05 AM ET

Healthcare Providers and Services

Company Overview of Dana-Farber Cancer Institute, Inc.

Company Overview

Dana-Farber Cancer Institute, Inc. provides cancer treatment and research services for adults and children in the United States. It offers adult treatment and care services for blood, breast, cutaneous/skin, gastrointestinal, genitourinary, gynecological, head and neck, hematology, melanoma, neuro-oncology, sarcoma, and thoracic cancer; and cancer genetics and prevention services. The company also provides treatment and care for children with cancer, such as blood diseases, bone and soft tissue tumors, brain tumors, histiocytosis, Hodgkin lymphoma, kidney tumors, leukemia, neuroblastoma, non-Hodgkin lymphoma, and rare tumors program. In addition, it offers training in cancer treatment and re...

450 Brookline Avenue

Boston, MA 02215-5450

United States

Founded in 1947

Phone:

617-632-3000

Fax:

617-632-3057

Key Executives for Dana-Farber Cancer Institute, Inc.

Chief Executive Officer and President
Top Key
Age: 50
Chief Financial Officer and Assistant Treasurer
Chief Operating Officer and Executive Vice President
Age: 64
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2015.

Dana-Farber Cancer Institute, Inc. Key Developments

Eli Lilly and Company and Dana-Farber Cancer Institute Announce Research Collaboration

Eli Lilly and Company and Dana-Farber Cancer Institute announced a multiyear collaboration to research new medicines under development to fight cancer. As per the agreement, over the course of three years Dana-Farber will provide research and development expertise for a number of early-stage Lilly oncology compounds. Dana-Farber researchers and Lilly scientists will work collaboratively on preclinical and clinical studies, molecular studies of patient samples and the design and conduct of clinical trials, which may result in important advances in the science of cancer care. The agreement also allows Dana-Farber scientists to conduct independent studies on select Lilly compounds. Following research conducted at Dana-Farber, the evaluated compounds will still be fully owned by Lilly. Financial terms of the agreement are not being disclosed.

Massachusetts Life Sciences Center and Dana-Farber Cancer Institute Announce Official Opening of Dana-Farber's Molecular Cancer Imaging Facility

Dana-Farber Cancer Institute and the Massachusetts Life Sciences Center (MLSC) celebrated the official opening of Dana-Farber's Molecular Cancer Imaging Facility in Boston's Innovation District. The laboratory focuses on making chemical tracers that 'light up' cancer cells and molecular pathways, a technology for research on improving cancer diagnosis and developing precision drugs matched to individual patients. The Molecular Cancer Imaging Facility (MCIF) includes a cyclotron for making short-lived molecular imaging probes that are tracked by PET scanners. The process is key to evaluating experimental drugs and showing whether they hit vulnerable targets within cancer cells. Construction of the facility at Dana-Farber's Harbor Campus in South Boston's Innovation District was made possible through a $10 million grant from the MLSC, a state-funded investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing the state's 10-year, $1 billion Life Sciences Initiative.

Dana-Farber Cancer Institute, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015

Dana-Farber Cancer Institute, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Presentation Date & Speakers: May-29-2015, O. Prem Das, Chief Research Business Development Officer.

Similar Private Companies By Industry

Company Name Region
Edwards Medical Supply, Inc. United States
PathwayMD United States
Havenwyck Hospital Inc. United States
SunLink Healthcare LLC United States
Reliant Medical Group Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dana-Farber Cancer Institute, Inc., please visit www.dana-farber.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.